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et al., 2007). IFN-b signaling, in turn, sup-
presses chemokine secretion by micro-
glia, and this suppression decreases in-
filtration by peripheral immune cells. In
addition, IFN-b decreases the uptake
and presentation of other nervous tissue
antigens and inhibits the amplification of
inflammation via epitope spreading.
Recently, in another publication, Guo
et al. also examined the role of type 1
IFN signaling in EAE (Guo et al., 2008).
They too discovered that IFNAR-deficient
mice had defects in innate immune cell
function, but they report a striking differ-
ence between those reported by Prinz
et al. (2008) on the effects of type 1 IFN
on the development of T helper 17
(Th17) cells. Prinz et al. (2008) observed
no effect on the development of Th17
cells or expression of cytokines involved
in their function. In contrast, Guo et al.
(2008) demonstrated that the immuno-
suppressive effect of type 1 IFN is due to
the downregulation of IL-23 and upregula-
tion of IL-27, which is now known to inhibit
Th17 cell differentiation. What could be
the reason for these conflicting data?
On close inspection of the methods,
there is a considerable difference in how
each group induced disease. Prinz et al.
(2008) used much less mycobacterium in
the adjuvant than Guo (1 ug/ml versus
8 mg/ml). This difference could have a
profound influence on the activation and
cytokine production of the innate immune
system and could be the cause of this
important discordance in experimental
outcomes.
IFN-bhasbeenanexceptionally popular
therapy for relapsing remitting MS. Be-
cause we now understand that IFN-b is
a natural protector of brain tissue from in-
flammation, it is clear why exogenous ad-
ministration of this cytokine has beneficial
effects in diseases such as MS. However,
not all patients respond to treatment.
Therefore, defining the mechanisms re-
sponsible for the therapeutic effects of
IFN-b has high relevance. Future studies,
using both human and mouse models,
mustbedesigned toaddresswhatactually
happens when IFN-b is administered as
a therapy. Even though Prinz et al. (2008)
do not elucidate the therapeutic mecha-
nism of IFN-b, they describe an intriguing
mechanismbywhichnatural type1 IFNex-
pressed in the mouse suppresses inflam-
mationandautoimmunity in theCNS.Prinz
et al. (2008) have made an important dis-
covery that provides key information for
the community of scientists and physi-
cians interested in demyelinating diseases
such as MS and also for immunologists
interested in autoimmunity in general.
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Effective subunit vaccines must elicit strong CD4+ T cell responses. In this issue of Immunity, Malherbe et al.
(2008) find that the ability of adjuvants to stimulate high-avidity T cell responses correlates with Toll-like-
receptor engagement.Charlie Janeway referred to adjuvants as
‘‘the immunologist’s dirty little secret,’’
but they still offer the best hope for estab-
lishing safer and more effective subunit
vaccines (Janeway, 1989). Adjuvants are
nonspecific stimulators of the immune602 Immunity 28, May 2008 ª2008 Elseviersystem, and many are thought to operate
through activation of Toll-like receptors
on antigen-presenting cells (McKee et al.,
2007). However, the molecular mecha-
nisms underlying adjuvant effects have
not beenwell defined. Todesign adjuvantsInc.best suited to improvevaccine immunoge-
nicity without increasing unwanted side
effects, wemust first delineate the proper-
ties that define good adjuvants and then
elucidate theirmolecular effects. Theeffect
of adjuvants on T cell responses has, until
Immunity
PreviewsFigure 1. Adjuvants Regulate CD4+ T Cell Responses
The number and avidity of antigen-specific T cells that develop in response to protein antigen varies with adjuvant. The depot-forming, non-TLR-ligand adjuvant
alum elicits a small number of clonal PCC-specific T cells with relatively low-avidity TCRs. The depot-forming, multiple-TLR-ligand-containing adjuvant CFA
induces a larger number of clonal PCC-specific T cells with higher-avidity TCRs. The adjuvant that induced the highest number of PCC-specific T cells with
the highest avidity TCRs was MPL, a dispersable adjuvant that specifically stimulates TLR4.now, been relatively unexplored. In this
issue of Immunity, Malherbe et al. (2008)
show thatadjuvantshaveadifferential abil-
ity to stimulate high-avidity CD4+ T cells.
Effective and safe vaccines represent
one of the most important medical ad-
vances in human history. The scourge of
smallpox has been eradicated globally,
and thedevastationofparalyticpoliomyeli-
tis has been absent from the Americas
since 1991. Despite these historic suc-
cesses,many challenges in vaccine devel-
opment and use remain. To be effective,
a vaccine not only must stimulate the
appropriate immunologic response for
pathogen neutralization, such as antibody
production or cytotoxic T cell generation,
but alsomust promote long-lived immunity
via development of memory T cells. To be
safe, a vaccine must avoid generating
severe systemic inflammation when ad-
ministered. A perfect vaccine therefore
achieves robust and appropriate im-
munogenicitywithout undue inflammation.
Unfortunately, no vaccine is perfect. Live
attenuated viruses, still used to immunize
against measles, mumps, rubella, and
varicella, are safe for the majority of recip-
ients. However, the varicella vaccine can
cause severe disease if inadvertently given
toachildwithanunrecognized immunode-
ficiency (Gershon, 2003). Killed or inacti-
vated organisms are used for immuniza-
tion of diseases such as influenza and
polio, but inclusionofwholebacterial prod-
ucts can produce severe systemic side
effects.Prior to the introductionof theacel-
lular pertussis vaccine, use of whole-cellpertussis was associated with a relatively
high frequency of adverse events such as
high fevers, seizures, and encephalopathy
(Decker and Edwards, 2000). Subunit
vaccines avoid the side effects of whole-
cell or killed organisms and are safe for im-
munocompromised individuals, but they
can have decreased immunogenicity. For
example, the polysaccharide antigens of
the pneumococcal vaccinemust be conju-
gated to a protein carrier in order to elicit
a protective immune response in children
under two years of age, those most at
risk for severe pneumococcal infection.
Furthermore, use of the above strategies
has not yet enabled the development of
successful vaccines against some of the
biggest killers, such as malaria and HIV.
The absence of data regarding adjuvant
effects on T cells is due in part to the lack
of intermediatebiomarkersforTcell respon-
ses. Although antibodies can be followed
easily in the serum, T cell responses are
more difficult to assess. Despite the recent
advances in understanding T cell recogni-
tion of antigen, we still do not know
precisely what features of the TCR:pMHC
interactionaredesirable inavaccine.Cases
have been made for the measurements
of affinity and kinetics such as KD, Koff,
or two-dimensional KD (Qi et al., 2006;
Williams et al., 1999), but no single parame-
tercompletelycorrelateswith the sensitivity
of the T cell. Furthermore, the effects of
different adjuvants on these parameters
have not been determined.
Here, Malherbe et al. (2008) use the
response of naive T cells to pigeon cyto-Immchrome C (PCC) to determine adjuvant
effects on naive T cell responses. This
system enables the analysis of antigen-
specific responses in a normal (non-
TCR-transgenic) mouse. T cells specific
for PCC 94-103-I-Ek epitope fortuitously
utilize conserved Va11 and Vb3 TCR
chains. McHeyzer-Williams and Davis
(1995) exploited this feature of the PCC
response previously, showing that PCC
specific T cells could be purified from a
normal mouse through the use of mono-
clonal antibodies and then of single-cell
PCR to analyze the TCR chains. The in-
vention of MHC tetramers has greatly
expanded the ability of antigen-specific
T cells to be purified and the relative avid-
ity of the TCRs to be determined (Altman
et al., 1996; Moon et al., 2007). The
McHeyzer-Williams laboratory has estab-
lished a set of eight preferred features
within the CDR3 of the expressed TCRab
chains in PCC-specific T cells, with which
they can identify the responding clones
and categorize their avidity.
Malherbe et al. (2008) have now charac-
terized and compared the primary PCC-
specific T cell responses stimulated in
the presence of different adjuvants. They
tested five adjuvants: three depot-form-
ing (alum, CFA, IFA) and two dispersible
formulations (CpG and MPL). These adju-
vants also differed in their ability to en-
gage Toll-like receptors. Alum and IFA
contain no TLR ligand, whereas CFA
engages multiple TLRs, CpG engages
TLR9, and MPL engages TLR4. All adju-
vants stimulated PCC-specific T cellsunity 28, May 2008 ª2008 Elsevier Inc. 603
Immunity
Previewsbut differed in the number of antigen-spe-
cific T cells generated (Figure 1). Alum
induced the fewest number of T cells,
whereas MPL induced the most. Some-
what surprisingly, all adjuvants, regard-
less of TLR ligation, were able to induce
the clonal expansion of PCC-specific T
cells. However, important differences be-
tween adjuvants were revealed when the
avidity of the expanded T cells was char-
acterized by either the number of pre-
ferred features of the CDR3 or tetramer
binding. Alum, IFA, and CFA promoted
PCC-specific T cell clones that were of
lower avidity, whereas CpG and MPL
preferentially stimulated the higher avidity
T cell clones (Figure 1). Thus, the inclusion
of TLR agonists into the adjuvant formula-
tions directly correlated with increased
accumulation of higher-avidity T cells. In-
terestingly, the clonal selection of PCC-
specific T cells was independent of anti-
gen dose. This implies that there does
not appear to be interclonal competition
among CD4+ T cells for antigen, in con-
trast to what has been shown for CD8+ T
cells.
In summary, the system described by
Malherbe et al. (2008) represents an im-The Immunostimu
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In this issue of Immunity, Miller et al.
T cell responses after acute human
Several groups have demonstrated that
antiviral CD8+ T cell responses in mice
can be enormous—with virus-specific T
cells representing up to 50%–80% of the
total CD8+ T cell population at the peak
of the immune response and/or the ana-
tomical site of infection (Murali-Krishna
et al., 1998). Such dramatic T cell re-
sponses were thought to be associated
withonlya fewselect pathogens (e.g., lym-
phocytic choriomeningitis virus; LCMV) or
perhaps related to the large virus doses
604 Immunity 28, May 2008 ª2008 Elsevierportant step forward in quantifying the pa-
rameters of T cell responses that may cor-
relate with vaccine efficacy. It will now be
critical to determine whether these five
adjuvants elicit similar responses with
different model antigens. With the clear
demonstration that adjuvant formulation
can substantially modify the number and
avidity of antigen-specific T cells selected
in response to soluble-protein immuniza-
tion, we can investigate the effect of these
different populations of T cells on the de-
velopment of T cell memory and effective
pathogen responses. For instance, this
system could be employed to determine
whether higher-avidity T cells result in
improved development of T cell memory.
Furthermore, this system could be ex-
ploited to clarify mechanisms by which
adjuvants operate. Open questions in-
clude whether adjuvants are acting upon
T cells, antigen-presenting cells, or both.
Also, although this study showed that
adjuvants that are TLR ligands induced
higher-avidity T cell responses, it is not
yet clear that TLR-agonist adjuvants will
markedly improve vaccine efficacy. How-
ever, the findings of Malherbe et al. (2008)
represent one more step along the roadlatory Power of Ac
Health & Science University, 505 NW 185th Ave
(2008) usemultiple independent tech
infection are much larger than previo
and invasive routes of infection (e.g., intra-
peritoneal administration) that are often
used during experimental infection of ani-
mals. Acute viral infection of humans, on
the other hand, was thought to result in
a much smaller CD8+ T cell response.
However, as described in this issue of
Immunity, Miller et al. (2008) provide
compelling evidence indicating that the
magnitude of CD8+ T cell responses iden-
tified in humans after acute viral infection
might indeed rival the magnitude of antivi-
Inc.toward the development of effective
subunit-based vaccines.
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Miller et al. (2008) analyzed virus-spe-
cific CD8+ T cell responses against two
unrelated viruses: yellow fever virus
(YFV) and vaccinia virus (VV). Although
both YFV and VV represent acute viral in-
fections, they differ in many ways. YFV is
a small RNA virus that encodes just ten
genes, and following subcutaneous inoc-
ulation, it spreads systemically, resulting
inn a transient viremia in the infected
